Methoxy- and fluoro-chalcone derivatives arrest cell cycle progression and induce apoptosis in human melanoma cell A375

Biological and Pharmaceutical Bulletin

Volumn 32, Issue 6, 2009, Pages 1109-1113

  Henmi, Kayo ^a   Hiwatashi, Yoko ^a   Hikita, Eri ^a   Toyama, Naoya ^a   Hirano, Toshihiko ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Apoptosis; Caspase 3; Cell cycle; Melanoma

Indexed keywords

3 TRIFLUOROMETHYL 2',4' DIMETHOXYCHALCONE; 3 TRIFLUOROMETHYL 4' METHOXYCHALCONE; 4 TRIFLUOROMETHYL 2' METHOXYCHALCONE; 4 TRIFLUOROMETHYL 4' METHOXYCHALCONE; ANTINEOPLASTIC AGENT; CASPASE 3; CHALCONE; CHALCONE DERIVATIVE; CONCANAVALIN A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA CLEAVAGE; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MELANOMA; MELANOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHALCONES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; INHIBITORY CONCENTRATION 50; LEUKOCYTES, MONONUCLEAR; MELANOMA; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 66549117514     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.32.1109     Document Type: Article

References (21)

1. Ishihara K., Saida T., Otsuka F., Yamazaki N., Int. J. Clin. Oncol., 13, 33-41 (2008).
2. Serrone L., Zeuli M., Sega F. M., Cognetti F., J. Exp. Clin. Cancer Res., 19, 21-34 (2000).
3. Luce J. K., Thurman W. G., Isaacs B. L., Talley R. W., Cancer Chemother. Rep., 54, 119-124 (1970).
4. Hill G. J., Moss S. E., Golomb F. M., Grage T. B., Fletcher W. S., Minton J. P., Krementz E. T., Cancer, 47, 2556-2562 (1981).
5. Falkson G., Van der Merwe A. M., Falkson H. C., Cancer Chemother. Rep., 56, 671-677 (1972).
6. Lee S. H., Sohn D. H., Jin X. Y., Kim S. W., Choi S. C., Seo G. S., Biochem. Pharmacol., 74, 870-880 (2007).
7. Kontogiorgis C., Mantzanidou M., Hadjipavlou-Litina D., Mini Rev. Med. Chem., 8, 1224-1242 (2008).
8. Edwards M. L., Stemerick D. M., Sunkara P. S., J. Med. Chem., 33, 1948-1954 (1990).
9. Sawle P., Moulton B. E., Jarzykowska M., Green C. J., Foresti R., Fairlamb I. J., Motterlini R., Chem. Res. Toxicol., 21, 1484-1494 (2008).
10. Motani K., Tabata K., Kimura Y., Okano S., Shibata Y., Abiko Y., Nagai H., Akihisa T., Suzuki T., Biol. Pharm. Bull., 31, 618-626 (2008).
11. Mukherjee S., Kumar V., Prasad A. K., Raj H. G., Bracke M. E., Olsen C. E., Jain S. C., Parmar V. S., Bioorg. Med. Chem., 9, 337-345 (2001).
12. Iwashita K., Kobori M., Yamaki K., Tsushida T., Biosci. Biotechnol. Biochem., 64, 1813-1820 (2000).
13. Kobori M., Shinmoto H., Tsushida T., Shinohara K., Cancer Lett., 119, 207-212 (1997).
14. Hirano T., Oka K., Takeuchi H., Sakurai E., Matsuno N., Tamaki T., Kozaki M., Transplantation, 57, 1341-1348 (1994).
15. Hirano T., Oka K., Tamaki T., J. Pharmacol. Exp. Ther., 273, 223-229 (1995).
16. Hirano T., Oka K., Kawashima E., Akiba M., Life Sci., 45, 1407-1411 (1989).
17. Fok J. Y., Ekmekcioglu S., Mehta K., Mol. Cancer Ther., 5, 1493-1503 (2006).
18. Bhat B. A., Dhar K. L., Puri S. C., Saxena A. K., Shanmugavel M., Qazi G. N., Bioorg. Med. Chem. Lett., 15, 3177-3180 (2005).
19. Lawrence N. J., Rennison D., McGown A. T., Ducki S., Gul L. A., Hadfield J. A., Khan N., J. Comb. Chem., 3, 421-426 (2001).
20. Stennicke H. R., Salvesen G. S., Biochim. Biophys. Acta, 1477, 299-306 (2000).
21. Danial N. N., Korsmeyer S. J., Cell, 116, 205-219 (2004).